arrow
J

James Campling

Pfizer
H指数:11
被引数:639

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective

英格兰成人使用二十价肺炎球菌结合疫苗的成本效益及投资回报分析:基于社会视角的分析

2026-01-210
PRE
Incidence of community acquired lower respiratory tract disease in Bristol, UK, in 2020–2024: a prospective cohort study

2020—2024年英国布里斯托社区获得性下呼吸道疾病发病率:一项前瞻性队列研究

2025-12-090
OAAI
Changes in carriage and serotype diversity of Streptococcus pneumoniae and other respiratory pathobionts in the UK between pre-PCV13 (2006-10), early-PCV13 (2010-12) and late-PCV13 (2012-23) periods

英国Streptococcus pneumoniae及其他呼吸道共生致病菌的携带率和血清型多样性变化,比较了PCV13接种前的时期(2006-2010年)、PCV13早期接种时期(2010-2012年)和PCV13晚期接种时期(2012-2023年)。

2025-09-180
OAAI
Emergency department presentations of community-acquired lower respiratory tract disease in Bristol, UK: a prospective cohort study 2022-2023

英国布里斯托市社区获得性下呼吸道疾病的急诊就诊情况:一项2022-2023前瞻性队列研究

2025-05-160
OA
Non-pharmaceutical interventions for COVID-19 transiently reduced pneumococcal and Haemophilus influenzae carriage in a cross-sectional pediatric cohort in Southampton, UK

在英国南安普敦的横断面儿科队列中,对新型冠状病毒肺炎的非药物干预措施暂时减少了肺炎球菌和流感嗜血杆菌的携带

2024-08-061
OAAI
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom

肺炎球菌疾病风险增加的成年人接种肺炎球菌疫苗的证据综述: 英国风险组定义和疫苗接种覆盖率的优化

2023-09-1112
OA
Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A prospective cohort study
2022-10-0116
OA